This afternoon we watched Jazz Pharmaceuticals rise 6.3% to a price of $113.02 per share. The Mid-Cap Pharmaceutical company is now trading -37.41% below its average target price of $180.56. Analysts have set target prices ranging from $117.0 to $230.0 per share for Jazz Pharmaceuticals, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 6.8%, and a short ratio of 5.13. Since 2.78% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 97.1% of Jazz Pharmaceuticals's shares being owned by this investor type.
Institutions Invested in Jazz Pharmaceuticals
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Blackrock Inc. | 11% | 7,069,920 | $799,042,334 |
| 2024-03-31 | Vanguard Group Inc | 10% | 6,448,689 | $728,830,809 |
| 2024-03-31 | State Street Corporation | 4% | 2,462,135 | $278,270,489 |
| 2024-03-31 | Lsv Asset Management | 4% | 2,380,858 | $269,084,563 |
| 2024-03-31 | JP Morgan Chase & Company | 2% | 1,494,538 | $168,912,679 |
| 2024-03-31 | Polaris Capital Management Inc | 2% | 1,432,660 | $161,919,228 |
| 2024-03-31 | Capital World Investors | 2% | 1,427,860 | $161,376,732 |
| 2024-03-31 | Ameriprise Financial, Inc. | 2% | 1,368,949 | $154,718,611 |
| 2024-03-31 | Pacer Advisors, Inc. | 2% | 1,293,726 | $146,216,908 |
| 2024-03-31 | Renaissance Technologies, LLC | 2% | 1,165,568 | $131,732,491 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Jazz Pharmaceuticals.
